Subtype
Lung Carcinoma
CI-CAN-00001086Explore in graph →
2,130 active trials51 approved drugs598 evidence items
Loading cancer entity…
Loading cancer entity…
Subtype
CI-CAN-00001086Explore in graph →
Clinical trials
7,791 studies whose conditions map to this entity or one of its descendants. Status and phase are as posted on ClinicalTrials.gov. 50 studies per page.
Computedformula ci-trial-intel-v1 · interventional studies · entity + NCIt descendants · hover a figure for its formulaCompare cancersTerminated studies (1,177)
| NCT | Title | Status | Phase | Enrollment (n) | Sponsor | Countries | Last update | Source |
|---|---|---|---|---|---|---|---|---|
| NCT00199758 | Study of an Early Change of a Chemotherapeutic Doublet Versus Four Cycles of Chemotherapy in Advanced Non Small Cell Lung Cancer | completed | Phase 2 | 227 | University Hospital, LimogesOTHER | 1 | Jul 16, 2025 | clinicaltrials |
| NCT04120454 | Ramucirumab and Pembrolizumab for the Treatment of EGFR Mutant Recurrent or Metastatic Non-small Cell Lung Cancer | completed | Phase 2 | 6 | Ohio State University Comprehensive Cancer CenterOTHER | 1 | Jul 11, 2025 |
| clinicaltrials |
| NCT02611024 | Pharmacokinetic Study of Lurbinectedin in Combination With Irinotecan in Patients With Selected Solid Tumors | completed | Phase 1 / Phase 2 | 316 | PharmaMarINDUSTRY | 6 | Jul 9, 2025 | clinicaltrials |
| NCT03382561 | Cisplatin/Carboplatin and Etoposide With or Without Nivolumab in Treating Patients With Extensive Stage Small Cell Lung Cancer | completed | Phase 2 | 160 | National Cancer Institute (NCI)NIH | 1 | Jul 3, 2025 | clinicaltrials |
| NCT04400188 | A Study of Fluzoparib (SHR-3162) and Temozolomide With or Without SHR-1316 in Treating Patients With Replapsed Small Cell Lung Cancer | completed | Phase 1 / Phase 2 | 25 | Jiangsu HengRui Medicine Co., Ltd.INDUSTRY | 1 | Jun 29, 2025 | clinicaltrials |
| NCT02299141 | Nintedanib in Molecularly Selected Patients With Advanced Non-Small Cell Lung Cancer | completed | Phase 2 | 20 | Washington University School of MedicineOTHER | 1 | Jun 24, 2025 | clinicaltrials |
| NCT02705820 | Switch Maintenance Pembrolizumab in Patients With NSCLC After First Line Platinum Doublet Chemotherapy(SWIPE) | completed | Phase 2 | 48 | Bank of Cyprus Oncology CentreOTHER | 1 | Jun 17, 2025 | clinicaltrials |
| NCT02262325 | Hypofractionated Boost Before Chemoradiation for Patients With Stage II-III Non-small Cell Lung Cancer Unsuitable for Surgery | completed | Phase 2 | 21 | Ohio State University Comprehensive Cancer CenterOTHER | 1 | Jun 12, 2025 | clinicaltrials |
| NCT05253053 | To Evaluate Efficacy and Safety of TT-00420 (Tinengotinib) as Monotherapy and Combination Therapy in Patients With Advanced Solid Tumors | completed | Phase 1 / Phase 2 | 84 | TransThera Sciences (Nanjing), Inc.INDUSTRY | 1 | Jun 12, 2025 | clinicaltrials |
| NCT04358237 | Lurbinectedin (PM01183) Combined With Pembrolizumab in Small Cell Lung Cancer.(LUPER) | completed | Phase 1 / Phase 2 | 28 | Antonio Calles BlancoOTHER | 1 | Jun 4, 2025 | clinicaltrials |
| NCT03037385 | Phase 1/2 Study of the Highly-selective RET Inhibitor, Pralsetinib (BLU-667), in Participants With Thyroid Cancer, Non-Small Cell Lung Cancer, and Other Advanced Solid Tumors(ARROW) | completed | Phase 1 / Phase 2 | 590 | Hoffmann-La RocheINDUSTRY | 13 | May 31, 2025 | clinicaltrials |
| NCT03242915 | Pembrolizumab Plus Chemotherapy in NSCLC With Targetable Genetic Alterations After Progression on Targeted Agents | completed | Phase 2 | 33 | University of Michigan Rogel Cancer CenterOTHER | 1 | May 30, 2025 | clinicaltrials |
| NCT04068896 | Study of NGM120 in Subjects With Advanced Solid Tumors, Pancreatic Cancer, and Prostate Cancer Using Combination Therapy | completed | Phase 1 / Phase 2 | 89 | NGM Biopharmaceuticals, IncINDUSTRY | 1 | May 29, 2025 | clinicaltrials |
| NCT06208124 | A Study of IMM-6-415 in RAS/RAF Mutant Solid Tumors | completed | Phase 1 / Phase 2 | 30 | Immuneering CorporationINDUSTRY | 1 | May 28, 2025 | clinicaltrials |
| NCT01652820 | Chemotherapy/Radiotherapy Versus Concomitant Chemotherapy Followed by Radiotherapy in Stage IIIB Non-small Cell Lung Cancer(GECP0008) | completed | Phase 2 | 140 | Spanish Lung Cancer GroupOTHER | 0 | May 23, 2025 | clinicaltrials |
| NCT04314895 | Trial of NanoPac Intratumoral Injection in Lung Cancer | completed | Phase 2 | 18 | NanOlogy, LLCINDUSTRY | 1 | May 23, 2025 | clinicaltrials |
| NCT03845296 | Rucaparib in Treating Patients With Genomic LOH High and/or Deleterious BRCA1/2 Mutation Stage IV or Recurrent Non-small Cell Lung Cancer (A Lung-MAP Treatment Trial) | completed | Phase 2 | 64 | SWOG Cancer Research NetworkNETWORK | 1 | May 21, 2025 | clinicaltrials |
| NCT03704688 | Trial of Trametinib and Ponatinib in Patients With KRAS Mutant Advanced Non-Small Cell Lung Cancer | completed | Phase 1 / Phase 2 | 12 | Memorial Sloan Kettering Cancer CenterOTHER | 1 | May 16, 2025 | clinicaltrials |
| NCT04383938 | Phase 1/2 Study of APR-246 in Combination With Pembrolizumab in Subjects With Solid Tumor Malignancies | completed | Phase 1 / Phase 2 | 40 | Aprea TherapeuticsINDUSTRY | 1 | May 13, 2025 | clinicaltrials |
| NCT04993677 | A Study of SEA-CD40 Given With Other Drugs in Cancers | completed | Phase 2 | 77 | Seagen Inc.INDUSTRY | 6 | May 11, 2025 | clinicaltrials |
| NCT03554473 | M7824 and Topotecan or Temozolomide in Relapsed Small Cell Lung Cancers | completed | Phase 1 / Phase 2 | 37 | National Cancer Institute (NCI)NIH | 1 | May 9, 2025 | clinicaltrials |
| NCT04967417 | Pembrolizumab With Standard Cytotoxic Chemotherapy in Treatment Naive NSCLC Patients With Asymptomatic Brain Metastases(PHOEBS) | completed | Phase 2 | 13 | Samsung Medical CenterOTHER | 1 | May 9, 2025 | clinicaltrials |
| NCT00983307 | A Study of Erlotinib Plus Radiotherapy (RT) for Patients With Advanced or Inoperable Non-Small-Cell Lung Cancer | completed | Phase 2 | 17 | Sidney Kimmel Comprehensive Cancer Center at Thomas Jefferson UniversityOTHER | 1 | Apr 30, 2025 | clinicaltrials |
| NCT04075396 | A Study of Lazertinib in Participants With Epidermal Growth Factor Receptor (EGFR) Mutation Positive Advanced Non-Small Cell Lung Cancer (NSCLC) | completed | Phase 1 / Phase 2 | 29 | Janssen Research & Development, LLCINDUSTRY | 3 | Apr 29, 2025 | clinicaltrials |
| NCT02487095 | Trial of Topotecan With VX-970 (M6620), an ATR Kinase Inhibitor, in Small Cell Cancers and Extrapulmonary Small Cell Cancers | completed | Phase 1 / Phase 2 | 62 | National Cancer Institute (NCI)NIH | 1 | Apr 13, 2025 | clinicaltrials |
| NCT04720976 | JAB-3312 Based Combination Therapy in Adult Patients With Advanced Solid Tumors | completed | Phase 1 / Phase 2 | 58 | Allist Pharmaceuticals, Inc.INDUSTRY | 1 | Apr 11, 2025 | clinicaltrials |
| NCT04364620 | AB-16B5 Combined With Docetaxel in Subjects With Metastatic Non-Small Cell Lung Cancer (EGIA-002) | completed | Phase 2 | 35 | Alethia BiotherapeuticsINDUSTRY | 2 | Apr 6, 2025 | clinicaltrials |
| NCT03197467 | Neoadjuvant Anti PD-1 Immunotherapy in Resectable Non-small Cell Lung Cancer(NEOMUN) | completed | Phase 2 | 30 | AIO-Studien-gGmbHOTHER | 1 | Apr 4, 2025 | clinicaltrials |
| NCT04735068 | Binimetinib and Hydroxychloroquine in Patients With Advanced KRAS Mutant Non-Small Cell Lung Cancer | completed | Phase 2 | 9 | Abramson Cancer Center at Penn MedicineOTHER | 1 | Apr 1, 2025 | clinicaltrials |
| NCT05298176 | Combining Afatinib and Concurrent Chemotherapy, Followed by Osimertinib and Concurrent Chemotherapy, in Untreated EGFR Positive NSCLC Tumors(COMBINATION) | completed | Phase 2 | 5 | Amsterdam UMC, location VUmcOTHER | 1 | Mar 28, 2025 | clinicaltrials |
| NCT03631784 | A Trial of Pembrolizumab in Combination With Chemotherapy and Radiotherapy in Stage III NSCLC (KEYNOTE-799, MK-3475-799)(KEYNOTE-799) | completed | Phase 2 | 216 | Merck Sharp & Dohme LLCINDUSTRY | 10 | Mar 25, 2025 | clinicaltrials |
| NCT02582125 | ONO-4538 Study in Patients With Advanced Non-Small Cell Lung Cancer | completed | Phase 2 | 53 | Ono Pharmaceutical Co., Ltd.INDUSTRY | 1 | Mar 24, 2025 | clinicaltrials |
| NCT04003246 | Phase II Concurrent Durvalumab and Radiotherapy for for Stage III Non-Small Cell Lung Cancer | completed | Phase 2 | 10 | University of Texas Southwestern Medical CenterOTHER | 1 | Mar 21, 2025 | clinicaltrials |
| NCT02437136 | Ph1b/2 Dose-Escalation Study of Entinostat With Pembrolizumab in Non-small Cell Lung Cancer (NSCLC) With Expansion Cohorts in NSCLC, Melanoma, and Colorectal Cancer (CRC) | completed | Phase 1 / Phase 2 | 191 | Syndax PharmaceuticalsINDUSTRY | 1 | Mar 20, 2025 | clinicaltrials |
| NCT04256707 | Relative Bioavailability/Bioequivalence of Different Formulations of Selinexor, the Impact of Hepatic Impairment on Selinexor Pharmacokinetics, Tolerability and Antitumor Activity of Selinexor Combination Treatment(SPRINT) | completed | Phase 1 / Phase 2 | 126 | Karyopharm Therapeutics IncINDUSTRY | 1 | Mar 19, 2025 | clinicaltrials |
| NCT02489903 | RRx-001 in Lung Cancer, Ovarian Cancer and Neuroendocrine Tumors Prior to Re-administration of Platinum Based Doublet Regimens (QUADRUPLE THREAT) | completed | Phase 2 | 139 | EpicentRx, Inc.INDUSTRY | 1 | Mar 17, 2025 | clinicaltrials |
| NCT05058560 | Tislelizumab in Addition to BACE in Patients with NSCLC | completed | Phase 2 | 30 | The First Affiliated Hospital of Zhengzhou UniversityOTHER | 1 | Mar 13, 2025 | clinicaltrials |
| NCT05505825 | A Study of AK104 in Combination With Chiauranib in Patients With Extensive Stage Small Cell Lung Cancer | completed | Phase 1 / Phase 2 | 36 | AkesoINDUSTRY | 2 | Mar 12, 2025 | clinicaltrials |
| NCT02535338 | Erlotinib Hydrochloride and Onalespib Lactate in Treating Patients With Recurrent or Metastatic EGFR-Mutant Non-small Cell Lung Cancer | completed | Phase 1 / Phase 2 | 11 | National Cancer Institute (NCI)NIH | 1 | Mar 3, 2025 | clinicaltrials |
| NCT04880863 | NAP in Combination With Docetaxel Following Obinutuzumab Pretreatment in Subjects With Checkpoint Inhibitor Pretreated Advanced or Metastatic NSCLC(NT-NAP-102-1) | completed | Phase 2 | 38 | NeoTX Therapeutics Ltd.INDUSTRY | 1 | Mar 3, 2025 | clinicaltrials |
| NCT03543683 | Combination of Osimertinib and Aspirin to Treat 1st Generation EGFR-TKI Resistance in NSCLC | completed | Phase 2 | 115 | Daping Hospital and the Research Institute of Surgery of the Third Military Medical UniversityOTHER | 1 | Feb 27, 2025 | clinicaltrials |
| NCT02424617 | A Study of BGB324 (Bemcentinib) in Combination With Erlotinib in Patients With Non-Small Cell Lung Cancer | completed | Phase 1 / Phase 2 | 40 | BerGenBio ASAINDUSTRY | 1 | Feb 26, 2025 | clinicaltrials |
| NCT04997382 | Chemotherapy Combined with ICIs in First-line Alectinib Failed Patients with ALK-rearranged NSCLC(CLASSIC5) | completed | Phase 2 | 112 | Hunan Province Tumor HospitalOTHER | 1 | Feb 25, 2025 | clinicaltrials |
| NCT02597946 | Afatinib in NSCLC With HER2 Mutation | completed | Phase 2 | 18 | Boehringer IngelheimINDUSTRY | 2 | Feb 19, 2025 | clinicaltrials |
| NCT04357873 | Efficacy of Immunotherapy Plus a Drug in Patients With Progressive Advanced Mucosal Cancer of Different Locations(PEVOsq) | completed | Phase 2 | 112 | UNICANCEROTHER | 1 | Feb 19, 2025 | clinicaltrials |
| NCT03190174 | Nivolumab (Opdivo®) Plus ABI-009 (Nab-rapamycin) for Advanced Sarcoma and Certain Cancers | completed | Phase 1 / Phase 2 | 34 | Sarcoma Oncology Research Center, LLCOTHER | 1 | Feb 17, 2025 | clinicaltrials |
| NCT03669523 | Denosumab and Nivolumab Combination As 2d-line Therapy in Stage IV NSC Lung Cancer with Bone Metastases (DENIVOS)(DENIVOS) | completed | Phase 2 | 82 | Centre Hospitalier Annecy GenevoisOTHER | 1 | Feb 13, 2025 | clinicaltrials |
| NCT03414814 | Osimertinib for NSCLC With EGFR Exon 20 Insertion Mutation | completed | Phase 2 | 15 | Seoul National University HospitalOTHER | 1 | Feb 11, 2025 | clinicaltrials |
| NCT02733159 | Pembrolizumab in Patients With Non-Small Cell Lung Cancer and a Performance Status 2(PePS2) | completed | Phase 2 | 62 | University of BirminghamOTHER | 1 | Feb 10, 2025 | clinicaltrials |
| NCT04263051 | Evaluation of UCPVax Plus Nivolumab as Second Line Therapy in Advanced Non Small Cell Lung Cancer(Optim-UCPVax) | completed | Phase 2 | 60 | Centre Hospitalier Universitaire de BesanconOTHER | 1 | Feb 5, 2025 | clinicaltrials |
Data updated 22 days agoSource updated Jul 16, 2025source: clinicaltrials